Overview

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Status:
Completed

Trial end date:
2019-03-28

Target enrollment:

Participant gender:

Summary

This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).

Details

Lead Sponsor:

Bayer

Collaborator:

Janssen Research & Development, LLC

Treatments:

Rivaroxaban